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Abstract
Background: The purpose of this study was to measure the impact of an educational intervention on parents of
children taking methotrexate (MTX) for juvenile idiopathic arthritis (JIA).
Methods: This study was conducted using a pre- and postsurvey design. The parents of 100 children with JIA
taking MTX for at least 2 months were surveyed during a routine office visit. The parents completed an initial
questionnaire regarding the safe use, adverse effects, and guidelines for monitoring the toxicity of MTX. An
educational intervention was then administered, and an identical follow-up questionnaire was given during the
next office visit. Statistical analysis using a paired t-test (critical P value < 0.05) was performed on individuals who
answered both questionnaires.
Results: There were 100 responses to the initial questionnaire and 67 responses to the follow-up questionnaire.
The mean length of time between surveys was 2.9 ± 0.9 months. In those who completed both questionnaires,
the overall correct score increased significantly from 75.8% to 93.4%, respectively (P < 0.0001). Individuals scored
the lowest (49%) on the question that addressed MTX’s impact on pregnancy and fertility.
Conclusions: MTX knowledge may be less than expected in the parents of children with JIA. Brief educational
interventions in the pediatric subspecialty practice can significantly affect a family’s understanding of their child’s
medications.
Introduction
Methotrexate (MTX) is the most commonly used dis-
ease-modifying antirheumatic drug (DMARD) for the
treatment of juvenile idiopathic arthritis (JIA) [1]. It is
an antimetabolite that inhibits DNA and purine synth-
esis, commonly used as a cytotoxic agent for childhood
malignancy in various regimens. At lower doses, MTX
(≤25 mg) acts as an anti-inflammatory agent used for
the treatment of rheumatic disease; however, it still has
potential adverse effects [2]. Adult literature demon-
strates that up to 93% of those taking MTX for rheuma-
toid arthritis will develop at least one adverse effect [3].
The most commonly reported adverse effects are gas-
trointestinal (nausea and vomiting) although folic acid
can be used to reduce these symptoms. Ulcerative sto-
matitis and alopecia also occur but are much less com-
mon. Prescribers must be cautious in using MTX for
women of childbearing age because of fetal death and/or
congenital anomalies in pregnancy. Bone marrow sup-
pression may occur and result in anemia, leukopenia,
neutropenia, and/or thrombocytopenia. Immune sup-
pression may lead to opportunistic infections. MTX has
been associated with elevated transaminases and poten-
tial hepatotoxicity. Renal damage, pulmonary disease
and dermatologic reactions can occur as well [2,4-6].
Patients are advised to obtain routine laboratory tests
to monitor for potential toxicities. These include a com-
plete blood count, liver function tests, blood urea nitro-
gen, creatinine and urinalysis. Periodic liver biopsy is
not recommended for toxicity monitoring as it was in
the past. For some patients with pulmonary disease, a
chest x-ray and pulmonary function tests are also
obtained periodically; however, MTX-associated intersti-
tial lung disease is exceedingly rare in children [1].
In pediatric rheumatology practice, every parent and
age-appropriate patient receives instructions and infor-
mation on MTX use at the start of therapy. These
instructions can vary across practitioners and may not
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be repeated on follow-up visits. A previous study on
adults with RA taking MTX showed that knowledge of
the toxicity and safe use of MTX were significantly
improved by a patient education program [3]. There is a
limited amount of data on parental knowledge of MTX
use and educational interventions that may improve
their understanding. An observation was made that the
parents of children taking MTX are not always aware of
potential adverse effects, appropriate monitoring and
prevention of toxicity. As a quality improvement project,
the parents’ knowledge of the safe use, adverse effects
and guidelines for monitoring toxicity of MTX was
evaluated.
The primary aim was to determine whether educa-
tional interventions, including review of a MTX ques-
tionnaire and dispersal of a MTX brochure, were
effective in parental education regarding MTX use in
their son or daughter with JIA. It was also determined
which question was answered incorrectly most often,
and therefore which topics are important to emphasize
with parents regarding MTX therapy.
Methods
This quality improvement study was conducted as a pre-
and post-survey design over a six month period at the
Children’s Hospital of Pittsburgh Rheumatology Clinic.
Patients taking MTX were identified through chart
review the day of their visit. Parents of children with JIA
were asked to answer a five item questionnaire during a
routine outpatient visit:
1. How often should blood work be checked on a
child taking methotrexate?
(a) Every 4 weeks
(b) Every 6-8 weeks
(c) Every 3 months
(d) Every 6 months
2. What are the most common side effects of metho-
trexate?
(a) Upset stomach and nausea
(b) Skin rash and hives
(c) Dizziness and headaches
(d) Blurry vision and forgetfulness
3. Why should blood work be checked regularly in a
child taking methotrexate?
(a) Monitor for worsening of the arthritis
(b) Monitor for potential side effects
(c) For research studies
(d) Compare results to other patients with similar
disease
4. Why do we prescribe folic acid?
(a) It helps with the arthritis symptoms
(b) It helps to prevent side effects of methotrexate
(c) It helps prevent the eye disease associated with
arthritis
(d) It helps with morning stiffness
5. How will methotrexate affect a child’s ability to
have children in the future?
(a) It has no affect but will cause birth defects if
taken by women at the time of conception or
pregnancy
(b) It will cause problems for women who want to
get pregnant many years after the drug is stopped
(c) It will cause lower sperm counts in men many
years after the drug is stopped
(d) It has no consequence on fertility or pregnancy
*Correct Responses: 1(b); 2(a); 3(b); 4(b); 5(a).
The questionnaire was developed by consensus of the
physicians in the division and was based on information
that was thought to be essential for parents to under-
stand regarding MTX therapy. The questions were
mainly derived from a brochure provided by the Arthri-
tis Foundation which is given to patients that are
initiated on MTX therapy for rheumatic conditions.
There was no pilot testing of the questions; however,
some content was similar to that from a previous study
conducted on adults with RA [3], providing face validity
of the questions and to ensure parents’ comprehension
when they were asked if they understood the questions
prior to answering them. The child had to have been on
MTX for at least 2 months and had to meet classifica-
tion for JIA according to the International League of
Associations for Rheumatology to be enrolled [7]. Some
patients were concomitantly using biologic agents (27%)
and/or corticosteroids (5%).
A single physician (AP) reviewed the results of the
questionnaire with the parents in a standardized fashion
and provided literature on MTX. The literature provided
was a brochure from the Arthritis Foundation from
which the questions were derived. During the next rou-
tine clinic visit, a follow-up questionnaire identical to
the first was given to the parents. Some patients did not
have a scheduled follow-up visit in the allotted time,
were taken off MTX, or had a different caregiver present
at the second visit; therefore, fewer participants
answered the follow-up questionnaire. The patient
demographics were not significantly different between
those who answered the follow-up questionnaire and
those who did not. Statistical analysis with a paired
t-test (critical P value < 0.05) was used to compare
Patel et al. Pediatric Rheumatology 2010, 8:25
http://www.ped-rheum.com/content/8/1/25
Page 2 of 5
mean scores (pre- and post-) for those individuals who
answered both questionnaires. It was also determined
whether the percentage correct was different between
male versus female parents, length of MTX use, and
subtype of disease using the Mann-Whitney U test
(critical P value < 0.05). In the few cases in which both
parents came to the initial visit, only one parent
answered the questionnaire.
Results
The first 100 parents who were approached answered the
initial questionnaire. Sixty-seven of the initial 100
answered the follow-up questionnaire. The patient
female-to-male ratio was 3:1 with an age range of 1-21
years old (mean of 9.9 ± 4.7 and median of 10). The most
common subtype of JIA was rheumatoid factor (RF) (-)
polyarticular disease (39%). The range of MTX dose was
5-25 mg (mean of 17.6 ± 5.1 and median of 18), with 56%
taking oral tablets and 44% receiving subcutaneous injec-
tions. The duration of MTX therapy when initially sur-
veyed ranged from 2-96 months (mean of 24.3 ± 21.8
months and median of 18). In those who completed both
questionnaires (n = 67), the overall score on the initial
questionnaire was 75.8% ± 20.8 and the overall score on
the follow-up questionnaire was 93.4% ± 10.7. The differ-
ence between these scores using a paired t-test was statis-
tically significant (P < 0.0001). The mean length of time
between questionnaires was 2.9 ± 0.9 months.
The percentage of correct responses initially for ques-
tions 1-5 were 66%, 81%, 87%, 94% and 49%, respectively.
The percentage of correct responses in the follow-up
questionnaire for questions 1-5 were 95%, 94%, 97%,
100% and 77.6%, respectively. The individual question
results are shown in Figure 1; all follow-up scores were
significantly higher than initial scores. The lowest initial
score was on question 5 (49.0%), which addressed MTX
impact on pregnancy and fertility. There was no signifi-
cant difference in score based on a male vs. female par-
ent, different subtypes of arthritis or duration of MTX
use (Table 1). The time points analyzed were 2-6, 7-12,
13-24, 25-36, 37-48 and over 48 months of MTX use.
Some parents admitted that they did not review the
MTX literature that was given to them on the initial visit.
The number who actually read the literature provided
Figure 1 Initial and follow-up responses (n = 67).
Table 1 Demographics and scores by sex of parent, subtype of disease and duration of methotrexate use
Characteristic n = 100 (%) Initial n = 67 (%) Follow-Up
Sex of parent1
Female 73 (73%) 77.3 ± 20.9 49 (73%) 93.5 ± 11.1
Male 27 (27%) 71.9 ± 18.6 18 (27%) 93.3 ± 9.7
Diagnosis1
Oligoarticular: Persistent 34 (34%) 74.1 ± 21.2 21 (31%) 94.3 ± 11.2
Oligoarticular: Extended 5 (5%) 64.0 ± 35.8 4 (6%) 95.0 ± 10.0
Polyarticular: RF (-) 39 (39%) 81.0 ± 18.3 25 (38%) 96.0 ± 8.2
Polyarticular: RF (+) 4 (4%) 75.0 ± 25.2 3 (4%) 93.3 ± 11.5
Enthesitis-related 6 (6%) 76.7 ± 15.1 5 (7%) 88.0 ± 11.0
Psoriatic 10 (10%) 70.0 ± 14.1 7 (11%) 91.4 ± 10.7
Systemic 2 (2%) 60.0 ± 28.3 2 (3%) 70.0 ± 14.1
MTX duration, months1
2-6 26 (26%) 75.4 ± 18.2 14 (21%) 95.7 ± 11.6
7-12 15 (15%) 74.7 ± 17.7 13 (20%) 89.2 ± 10.4
13-24 21 (21% 81.9 ± 18.9 13 (20%) 92.3 ± 13.0
25-36 14 (14%) 80.0 ± 24.8 9 (13%) 97.8 ± 6.7
37-48 11 (11%) 72.7 ± 20.5 9 (13%) 95.6 ± 8.8
>48 13 (13%) 66.2 ± 23.6 9 (13%) 91.1 ± 10.2
1The sex of parent, subtype of disease and MTX duration did not show a significant difference in questionnaire scores (Mann-Whitney U test used for statistical
analyses). RF, rheumatoid factor; MTX, methotrexate.
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was not analyzed because many patients “did not remem-
ber” if they read it.
Discussion
This study demonstrated that a simple teaching inter-
vention and distribution of literature regarding MTX
significantly improved the knowledge of parents of chil-
dren with JIA. The impact of this intervention was not
dependent on any patient or parent characteristics, such
as subtype of arthritis, length of MTX use or male or
female parent. It is difficult to assess whether distributed
literature or discussion regarding the questionnaire
enhanced their knowledge of MTX. Both approaches to
education may be important because not all individuals
learn in the same way. This is not time-consuming as
the questionnaire, counseling and distribution of the lit-
erature were accomplished in <10 min. The fact that the
majority of parents could not recall whether they had
reviewed the literature is a limitation in interpreting the
effect of the literature. Another limitation is the lack of
data available regarding the socioeconomic status and
education level of the individuals who participated.
The results of this study emphasize that the parents of
children taking MTX do not always fully understand the
potential adverse effects of this medication. The majority
of parents were aware of the need for monitoring
laboratory tests, the common side effects of MTX and
the use of folic acid. There was a lack of knowledge
initially on MTX adverse effects on pregnancy (change
in score from 49% correct to 77.6% correct). The aver-
age age of the patient during this study was 9.9 years
old, reflecting that many were prepubertal when MTX
was initiated. Healthcare workers may not have dis-
cussed pregnancy-related issues during the initiation of
MTX due to the young age of the population. Another
possibility is that the parents may not have been con-
cerned about these issues because of the age of their
child. Regardless of the cause, healthcare providers
should consider discussing MTX and pregnancy more
often and at an earlier age to establish awareness. There
is limited data on children with JIA and pregnancy;
however, adolescent pregnancy is always a concern,
regardless of chronic disease.
A study of quality indicators showed that there was
significant variability in providing adult rheumatoid
arthritis patients with discussions on MTX and in
obtaining appropriate monitoring studies [8]. Providing
literature regarding potential medication toxicities
through electronic medical records could standardize
this process to decrease this variability as well as satisfy
new regulatory agency requirements mandating that
healthcare workers demonstrate quality of care assur-
ance and improvement [9]. If one provided this informa-
tion with the printed prescriptions, the quality indicators
performance might improve; however, the patient or
parent is expected to read this information to gain
understanding. This does not always occur, so one still
may need to provide information verbally on medica-
tions during clinic visits.
It has been recommended that educating families
about goals of treatment and how to minimize treat-
ment side effects may enhance adherence [10]. A direct
correlation between improved medication knowledge
and enhancing adherence cannot be made from this
study but may be interesting to investigate in future
studies.
In summary, there can be a lack of knowledge regard-
ing the use and common adverse effects of MTX in JIA.
The parent understands the use and toxicity of MTX
can be improved with education. This can be done with
a combination of verbal information by a healthcare
provider and written literature on MTX. Pediatric rheu-
matologists should consider repetitive education when
teaching families about DMARDs, which can be
achieved in a short amount of time and enhance paren-
tal knowledge of MTX use and toxicity.
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